News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 635 results
June 2021
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphomaPrimary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion(1) Robust response observed in heavily pretreated patients in…
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patientsMONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS…
-
Media ReleaseNovartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
-
Media ReleaseNovartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasisApproval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)…
May 2021
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical programBEOVU (brolucizumab-dbll) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one…
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and careBlack women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with…
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus afliberceptIn KESTREL and KITE, BEOVU (brolucizumab-dbll) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 53
- › Next page